
|Articles|February 1, 2002
Daptomycin impressive against dual staph, strep skin infections
Chicago - Daptomycin (Cidecin), a novel lipopeptide antibiotic, showed a trend toward an improved clinical response compared to current standard therapy in the treatment of complicated skin and soft tissue (cSST) infections caused by dual infection with
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











